Journal Mobile Options
Table of Contents
Vol. 149, No. 2, 2009
Issue release date: May 2009
Section title: Original Paper
Int Arch Allergy Immunol 2009;149:127–132
(DOI:10.1159/000189195)

Increases in Urinary 9α,11β-Prostaglandin F2 Indicate Mast Cell Activation in Wine-Induced Asthma

Misso N.L.A.a, b · Aggarwal S.a, b · Thompson P.J.a, b · Vally H.a–c
aLung Institute of Western Australia Inc., Centre for Asthma, Allergy and Respiratory Research, bCooperative Research Centre for Asthma, University of Western Australia, Perth, W.A., and cNational Centre for Epidemiology and Population Health, ANU College of Medicine and Health Sciences, Australian National University, Canberra, A.C.T., Australia

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 6/16/2008
Accepted: 8/11/2008
Published online: 1/6/2009
Issue release date: May 2009

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Wine-induced asthmatic symptoms may be caused by sulphite additives. Prostaglandin (PG)D2 and cysteinyl leukotrienes (cysLT) are important mediators of asthmatic responses. To determine whether the sulphite additives in wine alter the production of PGD2 and cysLT, asthmatic patients with compelling histories of wine sensitivity were challenged with high- and low-sulphite wines; the urinary metabolites of PGD2 and cysLT were measured before and after challenge. Methods: Eight self-reporting wine-sensitive asthmatic patients completed double-blind challenges with high- and low-sulphite wines on separate days. Urine samples were collected before and after consumption of 150 ml of wine. Urinary concentrations of 9α,11β-PGF2 and leukotriene (LT)E4 were measured by enzyme immunoassay. Results: Urinary 9α,11β-PGF2 concentrations increased in all subjects following challenge with high-sulphite wine, and the median concentration increased 1.6-fold (p < 0.01). Urinary 9α,11β-PGF2 also increased 1.5-fold after low-sulphite wine challenge, although this did not reach statistical significance (p = 0.08). The median difference in 9α,11β-PGF2 concentration after high-sulphite wine challenge was not significantly different compared with that after low-sulphite wine challenge. Median urinary LTE4 concentrations did not change significantly after either wine challenge. Conclusions: Increased urinary 9α,11β-PGF2 concentrations following wine challenge suggest mast cell activation as a possible mechanism for wine-induced asthma, although this did not appear to be related to the sulphite additives in wine. Urinary 9α,11β-PGF2 may warrant further assessment as a potential biomarker of reactivity to wine in asthmatic subjects.

© 2009 S. Karger AG, Basel


  

Author Contacts

Correspondence to: Dr. Neil L. Misso
Lung Institute of Western Australia Inc.
Ground Floor, E Block, Sir Charles Gairdner Hospital
Verdun Street, Nedlands, W.A. 6009 (Australia)
Tel. +61 8 9346 3906, Fax +61 8 9346 2816, E-Mail nmisso@liwa.uwa.edu.au

  

Article Information

Received: June 16, 2008
Accepted after revision: August 11, 2008
Published online: January 6, 2009
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 1, Number of References : 29

  

Publication Details

International Archives of Allergy and Immunology

Vol. 149, No. 2, Year 2009 (Cover Date: May 2009)

Journal Editor: Valenta R. (Vienna)
ISSN: 1018-2438 (Print), eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 6/16/2008
Accepted: 8/11/2008
Published online: 1/6/2009
Issue release date: May 2009

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.